[Form 4] Acuren Corporation Insider Trading Activity

Rhea-AI Filing Summary

Acuren Corp. (TIC) Form 4: Director Elizabeth Meloy Hepding reported routine equity-compensation activity.

• 07/30/2025 – 10,000 previously granted restricted stock units (RSUs) vested and converted to an equal number of common shares (Code M) at a stated price of $0.
• 07/31/2025 – Granted 9,017 new RSUs (Code A) that will vest on 07/31/2026.

After these transactions the insider directly owns 10,000 common shares and holds 9,017 unvested RSUs. No open-market buying or selling occurred, and cash consideration was zero, so the filing has no immediate impact on share count, liquidity, or earnings. It signals continued equity alignment between the director and shareholders but is not in itself a market-moving event.

Insights

Securities Analyst

TL;DR: Routine RSU vesting/grant; insider now owns 10k shares and 9k RSUs—neutral impact.

The filing shows an automatic settlement of 10,000 RSUs and a follow-on award of 9,017 RSUs to Director Hepding. Both actions are typical under equity-compensation plans, carry no cash proceeds, and do not represent discretionary trading. The director’s direct share ownership rises to 10,000, modestly increasing insider alignment but adding an immaterial number to the public float. No valuation, guidance, or operational data accompany the filing, so it should be viewed as administratively neutral for investors.

Corporate Governance Expert

TL;DR: Standard equity-comp grant; maintains alignment, no governance red flags.

The one-for-one RSU conversion and annual RSU grant follow normal board compensation cadence. There is no evidence of opportunistic trading or 10b5-1 plan usage. The new award’s one-year cliff aligns with prevailing retention practices. Overall, the transaction supports ongoing director ownership without raising dilution or control concerns, leaving governance risk unchanged.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PIZZEY TALMAN

(Last) (First) (Middle)

C/O ACUREN CORPORATION

14434 MEDICAL COMPLEX DRIVE, SUITE 100

(Street)

TOMBALL TX 77377

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACUREN CORP [ TIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/30/2025		M		36,667	A	$0(1)	436,667	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	07/30/2025		M		36,667		(3)	(3)	Common Stock	36,667	$0	73,333	D
Performance Based Restricted Stock Units	(4)							(5)	(5)	Common Stock	110,000		110,000	D
Restricted Stock Units	(2)							(6)	(6)	Common Stock	73,333		73,333	D
Performance Based Restricted Stock Units	(4)							(7)	(7)	Common Stock	146,667		146,667	D

Explanation of Responses:

1. On July 30, 2025, 36,667 of the Reporting Person's restricted stock units were settled for an equal number of shares of the Issuer's Common Stock.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

3. These restricted stock units vest 33 1/3% on the first through third anniversaries of the grant date (July 30, 2024).

4. Each performance based restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

5. Subject to the volume weighted average price ("VWAP") of the Issuer's Common Stock reaching a specified price over a ten (10) consecutive trading day period at any time during the period commencing on February 18, 2025 and ending on July 30, 2029 (the "VWAP Achievement Period"), these performance based restricted stock units shall vest on the later of (x) July 30, 2025 and (y) the calendar day following the last day of the VWAP Achievement Period.

6. These restricted stock units vest on the third anniversary of the grant date (April 11, 2025).

7. These performance restricted stock units have a three-year performance period and to the extent earned will vest on April 11, 2028. The number of shares of Common Stock that will be earned is subject to decrease based on the results of the performance condition.

	/s/ Fiona Sutherland, Attorney-in-Fact	08/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Acuren (TIC) shares does Director Hepding own after the Form 4 filing?

Following the reported transactions, she directly owns 10,000 common shares and 9,017 unvested RSUs.

What was the nature of the July 30, 2025 transaction reported in the Form 4?

10,000 RSUs vested and were automatically converted to common shares at $0 cost; no shares were sold.

Did the director purchase or sell TIC shares on the open market?

No. The filing records an RSU settlement and a new RSU grant—no open-market trades occurred.

When do the newly granted 9,017 RSUs vest?

They vest on July 31, 2026, one year from the grant date.

Does this Form 4 filing materially affect TIC’s share count?

The 10,000-share issuance is de minimis relative to typical float and should have no material impact on share count or EPS.